Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis
Launched by AHMED A. H. ABDELLATIF · Aug 26, 2016
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
Ginko Biloba (GKB) \& Glucosamine (GL) were formulated in different dosage forms such as capsules, hydrogel and spray. GKB\&GL were in filled in hard gelatin capsules as three formulae (GKB caps, GL caps and both as mixture in caps). Also, GKB\&GL were formulated in hydrogel using 2% carbopol 934 as three formulae (GKB only, GL only and both as mixture). The same also were formulated as spray using alcohol, water and glycerol in concentration of 60%, 20% and 20% respectively. The study included 5 trials, involving 35 participants. The oral formulae were tried on 30 participants having Tenia...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • It is important to follow up and collect data, preferably for six months for local and systemic activity of Ginkgo Biloba and Glucosamine, to establish whether the infection recurrent or not.
- Exclusion Criteria:
- • Larger numbers of participants having different kind of fungal infection are needed to test efficiency drug in order to produce more reliable data.
About Ahmed A. H. Abdellatif
Ahmed A. H. Abdellatif is a dedicated clinical trial sponsor with a focus on advancing medical research and enhancing patient care. With a strong background in clinical pharmacology and a commitment to ethical research practices, Abdellatif aims to facilitate innovative studies that explore new therapeutic options and improve treatment outcomes. By fostering collaboration among healthcare professionals, researchers, and regulatory bodies, he strives to ensure the integrity and efficacy of clinical trials while prioritizing patient safety and well-being. His work is characterized by a meticulous approach to trial design and execution, contributing to the advancement of medical knowledge and the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Assiut, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials